AbbVie to Present at the Barclays Global Healthcare Conference
Get Alerts ABBV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.8%
Revenue Growth %: +9.7%
Join SI Premium – FREE
NORTH CHICAGO, Ill., March 1, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2017. William Chase, executive vice president and chief financial officer, will present at 8 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at www.investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVieAbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs approximately 29,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abbvie-to-present-at-the-barclays-global-healthcare-conference-300415640.html
SOURCE AbbVie
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
- SUI Price Prediction Turns Bullish as DEX Volume Triples to $540M and Remittix Markets Passes $50M
- AltaPointe's Behavioral Health Crisis Center Surpasses $101 million in community savings
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Barclays, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share